Treatment with PHD2 inhibitor roxadustat in a syngeneic model of lung cancer and melanoma reduces tumor growth by increasing the macrophages’ phagocytic activity and by inducing tumor vessel normalization, through the PHD–HIF axis112 (Fig. 5). The gene discussed is EGLN1; the disease is neoplasm.